DaunoXome® (Liposomal Daunorubicin) for First-Line Treatment of Advanced, HIV-Related Kaposi’s Sarcoma

Kaposi’s sarcoma, the most common tumor occurring in human immunodeficiency virus (HIV)-infected individuals and persons with the acquired immunodeficiency syndrome (AIDS), has become a more aggressive, increasingly difficult-totreat tumor partly because of its rapid progression late in the course of AIDS.1–4 Despite significant progress in understanding and treating Kaposi’s sarcoma lesions cosmetically over the last 15 years, overall survival of patients with advanced, HIV-associated Kaposi’s sarcoma has remained unchanged,1 prompting continued research for effective and better tolerated therapies. By selectively enhancing drug delivery to tumor versus normal tissues, thereby enhancing the antitumor effects and limiting the toxicities of antineoplastic drugs, some liposomal delivery formulations have presented an exciting therapeutic advance in the treatment of advanced, HIV-associated Kaposi’s sarcoma.